Abstract: One aspect of the technology described herein relates to a method for treating a subject having a cancer. This method involves selecting a subject having cancer; administering, to the selected subject, a cytotoxic fusion protein comprising an N-terminus coupled to a C-terminus, wherein the N-terminus comprises diphtheria toxin fragments A and B and the C-terminus comprises human IL-2; and administering, to the selected subject, a programmed cell death-1 receptor (PD-1) pathway inhibitor to treat the cancer in the subject. Also disclosed is a method for sensitizing a target cell population to treatment with a PD-1 pathway inhibitor, as well as compositions and kits for use in treating a subject having cancer.

Abstract: Topical compositions comprising a corticosteroid and at least one penetration enhancing agent, wherein the composition is substantially free of propylene glycol.